Exercise of Warrants

ValiRx

19/01/2026 07:00

RNS Number : 3318P

ValiRx PLC

19 January 2026

 

 

ValiRx PLC

("ValiRx" or the "Company")

 

Exercise of Warrants

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health announces it has received notification for the exercise of warrants over 80,000 ordinary shares in the Company at an exercise price of 0.5 pence per share providing the Company with gross proceeds of £400 ("Warrant Exercise").

Application will be made to the London Stock Exchange to admit the 80,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 23 January 2026.  The new ordinary shares will rank pari passu with the existing ordinary shares.

For the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise, the enlarged issued share capital of the Company will comprise 742,801,072 ordinary shares of 0.1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

*** ENDS **

Engage with the ValiRx management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

Investor questions on this announcement
We encourage all investors to share questions on this announcement via our investor hub
https://valirx.com/link/exkQJy
ValiRx plc
Dr Mark Eccleston, CEO
Tel: +44 115 784 0025
www.valirx.com
Mark.Eccleston@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Ludovico Lazzaretti
Tel: +44 (0) 20 7213 0880
Shard Capital Partners LLP (Sole Broker)
Damon Heath
Tel: +44 (0) 20 7186 9000
V Formation (Public Relations)
Lucy Wharton - Senior PR Executive
Sue Carr - Director
+44 (0) 115 787 0206
www.vformation.biz
lucy@vformation.biz
sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
IOEBPMLTMTJBBTF